Pilot Study: Exploring Anakinra's Impact on ALS Progression

Topic

applied sciences

Frequently Asked Questions (FAQ)

What is Anakinra (ANA) and what is its intended use in this study? Anakinra (ANA) is a recombinant Interleukin-1 Receptor antagonist (IL-1RA), meaning it blocks the action of Interleukin-1. IL-1 is a pro-inflammatory cytokine. The intended use in this study is to investigate its anti-inflammatory properties in ALS patients, specifically those with predominant lower motor neuron involvement, to potentially reduce the “low-grade inflammation” associated with disease progression and improve outcomes.
What was the primary goal of this pilot study on Anakinra and ALS? The primary goal of this Phase IIb open-label pilot study was to assess the safety and tolerability of daily subcutaneous injections of Anakinra in ALS patients with dominant lower motor neuron involvement (specifically, those with Progressive Muscular Atrophy (PMA) and those with both upper and lower motor neuron signs). The study also aimed to investigate potential effects on ALS progression and inflammatory markers.
Who were the participants in the Anakinra ALS study, and what were the inclusion criteria? The study included 19 ALS patients (17 male, 2 female). Key inclusion criteria were a vital capacity of over 50% and a dominant lower motor neuron presentation. The study enrolled both patients with PMA (pure lower motor neuron involvement) and those with a combination of upper and lower motor neuron signs.
What were the main findings of the Anakinra ALS pilot study regarding safety and tolerability? The study concluded that daily subcutaneous injection of Anakinra in ALS patients was safe and well-tolerated, thus achieving the primary endpoint. Common side effects included injection site reactions (which decreased in intensity and frequency over time) and mild to moderate headaches. One serious adverse event (abdomineller abscess formation after PEG placement) led to discontinuation of Anakinra and required antibiotic treatment.
Did the study find any effects of Anakinra on disease progression in ALS patients? The study did not definitively prove that Anakinra slowed disease progression. While the group with PMA showed a trend (p=0.09) toward slower progression compared to those with mixed upper and lower motor neuron signs, the authors caution that this could be due to the naturally slower progression rate observed in PMA compared to typical ALS. The study was not large or controlled enough to definitively attribute this trend to the medication.
What effect did Anakinra have on inflammatory markers in the study participants? The study showed a significant reduction in serum fibrinogen levels throughout the observation period (p=0.0053 at week 4 and p=0.0002 at week 8). Fibrinogen is a marker of systemic inflammation, so this reduction suggests that Anakinra might have a positive effect on the low-grade inflammation associated with ALS.
What were the limitations of this study, and what future research is recommended? The main limitations of this study were the small sample size and the open-label, uncontrolled design (meaning there was no placebo group for comparison). The authors state that because of this they could not determine the effectiveness of the medication. Therefore, the authors recommend a placebo-controlled Phase III study to further investigate the potential efficacy of Anakinra in ALS, specifically in patients with lower motor neuron involvement.
What is the rationale for targeting inflammation in ALS, as explored in this study? The rationale is based on evidence that neuroinflammation, characterised by the activation of microglia and increased levels of pro-inflammatory cytokines (like IL-1β, TNFα, and IL-6) in the spinal cord and cerebrospinal fluid, is observed in both ALS patients and animal models of the disease. Systemic inflammation markers such as fibrinogen also increase with disease progression. By using Anakinra, the study sought to mitigate this inflammation and potentially slow disease progression.

Significance

Understanding these findings helps advance our knowledge and inform better decisions. This research represents an important contribution to the field. For the full details, watch the video above and explore the linked resources.

Resources & Further Watching

Read the paper ‘Anakinra bei der ALS mit dominanter Affektion des 2. Motoneurons – eine explorative Pilotstudie’ written by André Maier, Nikolaus Deigendesch, Christoph Münch, Teresa Holm, Robert Meyer, Thomas Meyer and Arturo Zychlinsky

💡 Please don’t forget to like, comment, share, and subscribe!

Youtube Hashtags

#medicine #als #science

Youtube Keywords

pilot study exploring anakinra s impact on als progression

ResearchLounge

https://researchlounge.org/applied-sciences/medicine/pilot-study-exploring-anakinras-impact-on-als-progression/